Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

24.55
Delayed Data
As of Sep 30
 -0.50 / -2.00%
Today’s Change
18.55
Today|||52-Week Range
182.64
-75.85%
Year-to-Date
Analyst Says Cooper is Poised to Gain Market Share
Sep 30 / TheStreet.com - Paid Partner Content
Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says
Sep 26 / TheStreet.com - Paid Partner Content
Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc
Sep 30 / MotleyFool.com - Paid Partner Content
Trending Tickers: TWTR, VRX, ENDP, RIG
Sep 26 / TheStreet.com - Paid Partner Content
No Matter Who Becomes President, Valeant Pharmaceuticals Could Lose Pricing Power
Sep 29 / MotleyFool.com - Paid Partner Content
Andrew Left Says Trump and Clinton Agree on Just One Thing
Sep 26 / TheStreet.com - Paid Partner Content
3 Stocks for Growth in 2017
Sep 29 / TheStreet.com - Paid Partner Content
Can You Guess Which Big Pharma Has Raised Its Drug Prices 5 Times Since June 2014?
Sep 26 / MotleyFool.com - Paid Partner Content
Here's Why You Shouldn't Pay Much Attention to Wall Street Analysts' Stock Ratings
Sep 27 / MotleyFool.com - Paid Partner Content
Is Valeant Pharmaceuticals Playing With Fire?
Sep 23 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close25.05
Today’s open25.15
Day’s range24.53 - 25.54
Volume14,489,117
Average volume (3 months)25,962,895
Market cap$8.4B
Dividend yield--
Data as of 4:01pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-35.55%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book1.42

Competitors

 Today’s
change
Today’s
% change
RDYDr.Reddy's Laborator...+0.18+0.39%
SGENSeattle Genetics Inc+0.72+1.35%
MNKMallinckrodt Plc+0.79+1.15%
JAZZJazz Pharmaceuticals...-1.53-1.24%
Data as of 4:04pm ET, 09/30/2016

Financials

Next reporting dateOctober 17, 2016
EPS forecast (this quarter)$1.79
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts

Search for Jobs